Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. Pediatr Blood Cancer 2008 Mar;50(3):679-80
Date
08/11/2006Pubmed ID
16900484DOI
10.1002/pbc.21009Scopus ID
2-s2.0-38549143161 (requires institutional sign-in at Scopus site) 17 CitationsAbstract
Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.
Author List
Burke MJ, Cohn SLAuthor
Michael James Burke MD Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Adrenal Cortex HormonesAdrenal Gland Neoplasms
Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Child Behavior Disorders
Child, Preschool
Combined Modality Therapy
Diagnostic Errors
Ganglioneuroblastoma
Humans
Immunoglobulins, Intravenous
Immunosuppressive Agents
Immunotherapy
Male
Opsoclonus-Myoclonus Syndrome
Psychomotor Disorders
Recurrence
Rituximab